secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K/A
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001213900-25-045098
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt files amendment with Evofem Q1 results; merger deadline extended to Sep 30, 2025
--------------------------------------------------------------------------------

- Evofem Q1 2025 product sales net $845K, down 77% YoY from $3.6M; net income of $956K vs net loss $4.8M.
- Fifth Amendment to merger agreement moves required close to Sep 30, 2025; Aditxt to invest $1.5M in April 2025.
- Aditxt terminated Appili Therapeutics arrangement agreement effective May 31, 2025; removed from pro forma.
- Evofem had working capital deficit of $65M, accumulated deficit $896.7M, and substantial doubt as going concern.
- Evofem common stock moved from OTCQB to OTC Pink in April 2025 after failing minimum bid price compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025045098/0001213900-25-045098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025045098/ea0242647-8ka5_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-045098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer